Cell Therapeutics (CTIC) 1.08 -0.02

CELL THERAPEUTICS
(CTIC) 1.08 -0.02

Last Trade:	1.08	Day Range:	1.07 - 1.09
Trade Time:	08:02PM	52wk Range:	0.95 - 2.40
Prev. Close:	1.10	Market Cap:	216.11M
Open:	1.09	Div Yield:	0
Volume:	1028866	PE:
EPS:	-0.96

The Latest On CTIC

Rodman & Renshaw Places Cell Therapeutics Under Review 1/30/12 2:22pm

Morning Market Losers 1/30/12 10:08am

Cell Therapeutics Plummeting on NDA Withdrawl 1/30/12 9:52am

From Earlier: Cell Therapeutics Withdraws New Drug Application for Pixuvri and Plans to Resubmit in 2012 1/30/12 6:46am

Solar Stocks to watch in the week ahead 1/28/12 5:44am

Few small caps on the watch list 1/24/12 5:48pm

From Earlier: Cell Therapeutic Announces FDA's Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012 1/3/12 7:16am

A Peek Into The Market Before The Trading Starts 12/19/11 7:30am

Cell Therapeutics Retires Remaining Convertible Debt 12/19/11 6:54am

Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia 12/13/11 7:26am

Stocks To Watch For December 12 12/12/11 3:28am

Investor Ideas' Thursday's Biotech Stocks to Watch 12/9/11 12:22pm

Rodman & Renshaw Places Cell Therapeutics Under Review 1/30/12

Morning Market Losers 1/30/12

Cell Therapeutics Plummeting on NDA Withdrawl 1/30/12

From Earlier: Cell Therapeutics Withdraws New Drug Application for Pixuvri and Plans to Resubmit in 2012 1/30/12

Solar Stocks to watch in the week ahead 1/28/12

Few small caps on the watch list 1/24/12

From Earlier: Cell Therapeutic Announces FDA's Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012 1/3/12

A Peek Into The Market Before The Trading Starts 12/19/11

Cell Therapeutics Retires Remaining Convertible Debt 12/19/11

Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia 12/13/11

Stocks To Watch For December 12 12/12/11

Investor Ideas' Thursday's Biotech Stocks to Watch 12/9/11

Solar Stocks to watch in the week ahead 1/28/12

Few small caps on the watch list 1/24/12

Stocks To Watch For December 12 12/12/11

Hot Stocks to Watch For Short Term 12/6/11

Celgene Earnings Preview: Analysts Expect Higher EPS, Revenue 10/25/11

Wednesday's Biotech Stocks Trading 9/8/11

Celgene Earnings Preview: Analysts Expect Falling Revenue, Rising EPS Over Last Quarter 7/25/11

Earnings Preview for Bristol Myers Squibb Company (BMY, CTIC) 4/27/11

Calls Purchased on Cell Therapeutics, Inc. (CTIC) 10/14/10

Puts Sold on Cell Therapeutics (CTIC) 8/13/10

Puts Purchased on Cell Therapeutics (CTIC) 6/28/10

Cell Therapeutics (CTIC) Plunges On Double Whammy 5/24/10

Rodman & Renshaw Places Cell Therapeutics Under Review 1/30/12

Rodman & Renshaw Upgrades Cell Therapeutics to Market Outperform, $2 PT 10/4/11

Rodman & Renshaw Reiterates Perform Rating on Cell Therapeutics 7/29/11

Rodman & Renshaw Maintains Market Perform on Cell Therapeutics 6/15/11

Axia Slashes Estimates for Cell Therapeutics (CTIC) 6/3/10

Trade CTIC
NOW!

Partner Headlines

These 4 Biotech Stocks Are a Buy Now 2/8/12

The 5 Dumbest Things on Wall Street This Week: Feb. 3 2/3/12

Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 10,000 Shares 1/31/12

Cell Therapeutics Pulls Cancer Drug After CEO Boasted About Approval Chances 1/30/12

Play TheStreet's FDA Drug-Approval Contest 1/23/12

US Panel to Review CTIC's Pixantrone - Analyst Blog 1/4/12

5 Under-$10 Stocks Set to Soar 12/29/11

The Worst Biotech CEO of 2011 Is ... 12/9/11

Press Releases

RBCC Enters New World of Opportunity 1/13/12 Business Wire Story

RBCC Advances Marketing Initiative Into Social Media 1/11/12 Business Wire Story

RBCC Showcases New Biotech Investment Model 1/3/12 Business Wire Story

RBCC Works to Take Biotech Out of the Lab and Into the Marketplace 12/22/11 Business Wire Story

RBCC: Stem Cell Research Market to 2017 Has Strong Pipeline 12/14/11 Business Wire Story

RBCC to Join With Life Science Research Group BioHouston 12/13/11 Business Wire Story

RBCC Signs Letter of Intent With Cutting-Edge Biosciences Firm 12/12/11 Business Wire Story

RBCC Establishes New BioSciences Headquarters in Houston 11/6/11 Business Wire Story

Biotech Stock Trade Review: Cell Therapeutics Report Featured on MicroStockProfit.com 8/30/11 GlobeNewswire Story

Get the latest CTIC stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for CELL THERAPEUTICS stock price.

CELL THERAPEUTICS by YCharts

Cell Therapeutics (CTIC) 1.08 -0.02

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On CTIC

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social